Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
01 October 2021 | Story Lunga Luthuli and Vicky Simpson | Photo Supplied
Anton Engelbrecht _ Farmovs researcher
Anton Engelbrecht, FARMOVS Bioanalysis Specialist.

“At FARMOVS, we have the opportunity to work with the world’s top pharmaceutical companies, where we form part of the evaluation of labelled and/or conjugated antigens and antibodies that are developed for accurate quantification of endogenous and pharmaceutical compounds. Alternatively, commercially available kits and reagents are also used for the same purpose if the sponsor cannot supply the customised antigens/antibodies. The developed assay methods are put through a rigorous validation assessment to confirm the selectivity, sensitivity, and robustness of the assay,” says Anton Engelbrecht, FARMOVS Bioanalysis Specialist. 

FARMOVS, affiliated to the University of the Free State and operating from the Bloemfontein Campus, is a leading clinical research organisation (CRO) with a unique advantage. As the only on-site ISO15189-accredited and GLP-certified pharmacokinetic laboratory on the African continent, with numerous successful inspections by leading international regulators, it offers the highest quality bioanalytical services in a variety of biological matrices for the development of pharmaceutical products.

Engelbrecht says: “The team of bioanalytical experts thrives on the excitement generated by new discoveries that lead to better treatment of a variety of physiological diseases.”

Advanced technology backed by 47 years of bioanalytical experience

The clinical research organisation prides itself on advanced technology, backed by 47 years of bioanalytical experience. It has developed more than 580 validated analytical methods that adhere to the International Council for Harmonisation and the US Food and Drug Administration (FDA) guidelines. FARMOVS’ analytical methods have been used in more than 3 000 pre-clinical and clinical trials, contributing to the manufacturing of pharmaceutical drugs that are now used by households across the globe.

At FARMOVS, Engelbrecht says, it is a “world filled with novel methods of analysis and subsequent technological integration that expands the horizons of clinical research forming an important part of the discovery and production of new life-saving medicines that is constantly improving the quality of life of people all over the world”.

Engelbrecht says: “New technology and innovation should be the building blocks of any laboratory, and among these are the three fastest sample production members of our Immunochemistry Laboratory team – the STARLet pipettors.”

“We chose the Microlab® STARLet apparatus by Hamilton, because of its ability to perform sample analysis in large quantities at a greater speed by means of robotic pipetting and robotic automated microplate reading, which is a semi-automated process.”

He shared his excitement about improvements in the field of immunoassay development for the purposes of pharmaceutical analysis. This involves the preparation of unique immunoanalytical reagents, analysis of new categories of compounds, methodology, and instrumentation. The most important examples in this field are the continuous development of bead-based immunoassays.

Staying competitive in the industry

Immunoassay methods, such as radioimmunoassay (RIA) and enzyme immunoassay (EIA), among others, are also used at FARMOVS to analyse macromolecules for clients. “The RIA method is used for the determination of several pharmaceutically important compounds in biological fluids. RIA requires a sample containing the antigen of interest, a complementary antibody, and a radiolabelled version of the antigen. To increase the selectivity of an assay, all samples are pre-treated to eliminate high molecular weight endogenous matrix components, including anti-drug antibodies,” explains Engelbrecht.

Although FARMOVS has adequate technology to provide market-related results, the plan is to expand the team to include a multiplex platform that is a sensitive, fully automated immunoassay platform with multiplexing and custom assay capability. “This will pave the way to use an even more sensitive method to quantify biomarkers in the fields of oncology, neurology, cardiology, inflammation, and infectious disease. We aim to remain competitive in our industry, so naturally we must recruit the brightest and most evolved to join the team,” he says.

News Archive

UV belê in gehalte met strategiese fokusgroepe - Volksblad
2006-02-09

Verslaggewer
DIE Universiteit van die Vrystaat (UV) gaan vanjaar R10 miljoen beskikbaar stel om sekere van sy akademiese en navorsingsaktiwiteite in strategiese fokusgroepe te bedryf.

 

Volgens prof. Frederick Fourie, rektor en visekanselier van die UV, is hierdie ’n belegging in gehalte wat sal help om die UV nasionaal en internasionaal van ander universiteite in die wêreld te onderskei.

Tydens die amptelike opening van die UV verlede week het Fourie beklemtoon dat die strategiese fokusgroepe veel meer behels as net ’n herorganisering van gevestigde navorsingsgebiede.

“Sulke fokusgroepe behels ’n gefokusde deskundigheidsgebied en nie slegs navorsing nie, maar ook sterk voorgraadse en veral nagraadse onderrig en ’n potensieel sterk wetenskaplike grondslag vir samelewingsdiens.

“Strategiese fokusgroepe sal georganiseer word op die grondslag dat hierdie kennisgebiede op kort termyn die vlagskepe van die UV kan word. Dit beteken dat hierdie die gebiede is waarin die UV nou of in die toekoms waarskynlik ’n kompeterende voorsprong sal hê.”
Hy het gesê dit is belangrik dat die UV hom in die volgende fase van sy ontwikkeling posisioneer, nie net as ’n goeie onderrig- en navorsingsuniversiteit nie, maar ook as ’n universiteit wat in strategies belangrike kennisgebiede uitblink. Dit is noodsaaklik om energie en hulpbronne so te rig.

Nie alle akademiese en navorsingsaktiwiteite gaan egter hierdeur geraak word nie. ’n Breë ondersteuningsgrondslag is die afgelope paar jaar geskep vir uitnemende navorsing deur alle akademiese personeellede in hul eie navorsingsgebiede. Dié inisiatief sal naas die nuwe fokusgroepinisiatief steeds voortgaan.

Fourie sê die strategiese fokusgroepbenadering sal in lyn wees met die benadering wat ontwerp word deur die Nasionale Navorsingsraad (NNR) om nasionale prioriteite in berekening te bring. Breedweg is die vyf strategiese gebiede vir die UV voorlopig die volgende:
1. Voedselproduksie, voedselgehalte en voedselsekuriteit vir Afrika.
2. Ontwikkeling en streeksontwikkeling binne die Afrika-konteks.
3. Maatskaplike transformasie binne die Suider-Afrikaanse en Afrika-konteks.
4. Waterhulpbron- en ekostelselbestuur.
5. Tegnologie vir die toekoms. (’n Aparte fokusgroep rakende die chemiese nywerheid kan dalk bepaal word).

“Binne elk van hierdie gebiede kan ’n aantal nisgebiede geïdentifiseer word. Die fokusgebiede dek sowel die geestes- as die natuurwetenskappe, maar uiteraard kan en moet dit nie alles vir almal probeer wees nie,” sê Fourie.

Die presiese formulering en inhoud van die fokus- en nisgebiede sal nog bepaal word tydens gesprekke op die kampus. Dit sal met die hulp van kundiges buite die UV geskied.
Hy sê dit het sin dat ’n mediumgrootte universiteit soos die UV sy menslike hulpbronne, infrastruktuur, finansiële hulpbronne en intellektuele kundigheid sal konsentreer om te verseker dat ’n bydrae gelewer word tot Bloemfontein, die Vrystaat, die land en die Afrika-vasteland.

Hy sê van die uitvloeisels kan ’n belangrike impak op nywerheidsontwikkeling hê, byvoorbeeld in die chemiese bedryf, en dit mag ook ’n grondslag skep vir samewerking met provinsiale, nasionale en internasionale vennote.

Behalwe die R10 miljoen vir die vestiging van die fokusgroepe is daar die afgelope paar jaar groot bedrae beskikbaar gestel vir talle projekte om gehalte in onderrig en leer, in navorsing en ander gebiede te verbeter.

Berig verskyn in Volksblad - Dinsdag, 7 Februarie 2006

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept